FOR IMMEDIATE RELEASE |
27 April 2010 |
OXFORD BIOMEDICA PLC
ANNUAL GENERAL MEETING
Oxford, UK - 27 April 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
Resolution 12 (to empower the Directors to issue of up to 10% of current issued shares without reference to the pre-emption rights specified in the Companies Act 2006) was withdrawn prior to the AGM. The Directors took account of the proxy votes cast prior to the meeting, and intend to consult further with shareholders and to reconsider this at the 2011 AGM.
In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:
· Resolution 10: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £1,810,197 with a further aggregate nominal amount of £1,810,197 authorised in connection with a rights issue, or where applicable, other proportionate offer;
· Resolution 11: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;
· Resolution 13: to delete the provisions of the Company's former Memorandum and to adopt New Articles of Association, to implement changes brought in by Act; and
· Resolution 14: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting our website at www.oxfordbiomedica.co.uk
Certified copies of the document setting out the above resolutions passed at the 2010 AGM have been submitted to the UK Listing Authority and will shortly be made available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.
The results of the proxy voting in advance of the meeting shown below. On the Record Date (25 April 2010) there were 543,059,034 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For |
Votes at Chairman's Discretion |
Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast |
Result |
|
|
|
|
|
|
|
|
Ordinary resolutions (1-10) |
|
|
|
|
|
||
1 |
165,790,753 |
238,045 |
546,522 |
42,485 |
626,976 |
166,617,805 |
Passed |
|
|
|
|
|
|
|
|
2 |
88,357,708 |
257,173 |
546,522 |
77,315,101 |
768,277 |
166,476,504 |
Passed |
|
|
|
|
|
|
|
|
3 |
165,415,380 |
254,584 |
546,522 |
284,268 |
744,027 |
166,500,754 |
Passed |
|
|
|
|
|
|
|
|
4 |
165,523,398 |
254,584 |
546,522 |
174,688 |
745,589 |
166,499,192 |
Passed |
|
|
|
|
|
|
|
|
5 |
165,436,616 |
254,584 |
546,522 |
260,803 |
746,256 |
166,498,525 |
Passed |
|
|
|
|
|
|
|
|
6 |
164,747,244 |
254,584 |
546,522 |
175,313 |
1,521,118 |
165,723,663 |
Passed |
|
|
|
|
|
|
|
|
7 |
165,510,750 |
254,584 |
546,522 |
187,336 |
745,589 |
166,499,192 |
Passed |
|
|
|
|
|
|
|
|
8 |
165,536,287 |
265,399 |
546,522 |
152,546 |
744,027 |
166,500,754 |
Passed |
|
|
|
|
|
|
|
|
9 |
165,758,952 |
245,034 |
546,522 |
67,027 |
627,246 |
166,617,535 |
Passed |
|
|
|
|
|
|
|
|
10 |
164,243,469 |
264,897 |
546,522 |
135,606 |
2,054,287 |
165,190,494 |
Passed |
|
|
|
|
|
|
||
Special resolutions (11-14) |
|
|
|
|
|
||
11 |
165,463,182 |
267,316 |
546,522 |
253,448 |
714,313 |
166,530,468 |
Passed |
|
|
|
|
|
|
|
|
12 |
95,941,431 |
256,396 |
546,522 |
69,773,656 |
726,776 |
166,518,005 |
Withdrawn |
|
|
|
|
|
|
|
|
13 |
165,617,351 |
279,841 |
546,522 |
126,209 |
674,858 |
166,569,923 |
Passed |
|
|
|
|
|
|
|
|
14 |
163,396,762 |
263,382 |
546,522 |
2,395,193 |
642,922 |
166,601,859 |
Passed |
|
|
|
|
|
|
|
|
For further information, please contact:
|
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer |
Tel: +44 (0)1865 783 000
|
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson |
Tel: +44 (0)20 7588 2828
|
City/Financial Enquiries: Lisa Baderoon/ Mark Court Buchanan Communications
|
Tel: +44 (0)20 7466 5000 |
US Enquiries: Thomas Fechtner The Trout Group LLC |
Tel: (646) 378 2900 |
1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk